Circulating tumor cells (CTCs) present in the blood play important roles in cancer recurrence and metastasis, so the capture of CTCs has become a key issue in current cancer research. The method of using antibody-dependent immunomagnetic beads to capture CTCs has the characteristics of simple operation and rapidity, but there are problems such as large sample size requirement and high preparation cost. This study intended to use a new type of magnetic bead-plasma-modified graphene-coated iron nitride magnetic beads (G@FeN-MB) to carry out a preliminary study on the capture of circulating tumor cells in lung cancer. G@FeN-MB is covered by multi-layer graphene, and the core is iron nitride, which has stronger magnetic response than the commonly used iron oxide core. Graphene used as a magnetic bead coating shell has lower mass, higher stability and better biocompatibility than the SiO2 shell commonly used for magnetic beads on the market. In this study, two kinds of streptavidin magnetic beads were prepared by direct adsorption method and carbodiimide method respectively, and coupled with CTCs surface markers epithelial cell adhesion molecule (EpCAM) antibody preparation amino immunomagnetic beads (AIMB) and carboxylic immunomagnetic beads (CIMB). The results showed that both kinds of immunomagnetic beads could capture A549 cells, and the capture efficiency of AIMB was slightly higher than that of CIMB; in order to simulate the CTCs capture environment, healthy human blood was mixed with A549 cells to prepare cell mixtures of different concentrations, and the capture efficiency was higher by using AIMB captures A549 in human blood, and calculated the captured A549 and capture efficiency. The results showed that the capture efficiency of AIMB ranged from 66.25% to 81.50%. The feasibility of the method of preparing immunomagnetic beads based on G@FeN-MB was proved, and the obtained AIMB can be used for the sorting of lung cancer CTCs, showing the prospect of its application in clinical research.